Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06128694
Other study ID # Constatine Study
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 1, 2023
Est. completion date February 28, 2024

Study information

Verified date November 2023
Source Kalbe International Pte. Ltd
Contact Sri AP Simanullang, B.Pharm
Phone +62 81255434018
Email sri.simanullang@pharmametriclabs.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy oral nutrition supplement (ONS) in malnutrition/high risk malnutrition cancer patients. The main questions it aims to answer: 1. Are there differences in knowledge, attitude and behaviour scores in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS? 2. Is there a difference in nutritional status as assessed by average body weight, body mass index (BMI), haemoglobin (Hb), and albumin levels in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS?


Description:

This study uses an open label randomized clinical trial (RCT) design, double arm which allows subjects and researchers to know the interventions received by subjects conducted on cancer patient subjects. The study aims to compare knowledge, attitudes, and actions related to nutrition consumption through questionnaires, nutritional status assessed from anthropometry (BW and BMI), nutrient intake, as well as laboratory results (Hb, serum albumin), quality of life, and inflammatory markers (CRP, TNF-α, IL(interleukin)-1, IL-6) between the group of subjects who were given dietary counseling and ONS/oral nutrition supplement (intervention group) for 8 weeks compared to the group of subjects who only received dietary counseling and did not receive ONS (control group). Subjects who meet the inclusion criteria will be randomized into 2 groups using the stratified block randomization method stratified by age, and cancer type. Randomization will be carried out using a system in the application by stratifying the age of the subject based on the categorical age which has been categorized into 18-45 years and >45 years. For the type of cancer stratified into two, namely lung cancer and gynecology cancer according to the inclusion criteria. Both stratified will be randomized using excel application that will randomize 80 subjects at the beginning of the research study.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date February 28, 2024
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed lung and ob-gyn cancer patients (who have not undergone therapy or are currently undergoing therapy) - Aged greater than or equal to 18 years - Patients with a performance status score of 0 - 2 - Have inadequate food intake >5 days or: 1. BMI/body mass index <18.5 kg/m2 or 2. There is a >10% weight loss in the last 3-6 months or 3. BMI <20 kg/m2 or 4. There is >5% weight loss in the last 3-6 months with - Intervention group subjects are willing to take ONS orally for 8 weeks - Intervention group subjects, if they have taken other brands of ONS, are willing to stop taking ONS 2 weeks prior to the study. Exclusion Criteria: - Pregnant and breastfeeding, except for female subjects with one of the following criteria: 1. Have a history of hysterectomy (surgical removal of the uterus) and/or bilateral oophorectomy (surgical removal of the ovaries). 2. Medically confirmed ovarian failure (decreased ovarian function) 3. Achieved post menopausal status, defined as: cessation of regular menstruation for at least 12 consecutive months in the absence of pathological or physiological causes. - Renal insufficiency (eGFR ( Estimated Glomerular Filtration Rate ) <15 mL/min/1.73 m2 or significant increase in urea/creatinine or having to be on a low protein diet) - Liver insufficiency (SGOT (Serum Glutamic Oxaloacetic Transaminase) /SGPT (Serum Glutamic Pyruvic Transaminase) values =3 times the normal limit)

Study Design


Intervention

Dietary Supplement:
NUTRICAN
Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.

Locations

Country Name City State
Indonesia Persahabatan Hospital Jakarta

Sponsors (2)

Lead Sponsor Collaborator
Kalbe International Pte. Ltd Persahabatan Hospital

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nutrition consumption knowledge score To determine changes in nutrition consumption knowledge scores in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Knowledge score (5 questions): good (score>=8 ) moderate (score 5-8) poor (score 0-4);
8 weeks
Primary Nutrition consumption attitude score To determine changes in nutrition consumption attitudes score in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Attitude score (10 questions): good (score>=30 ) moderate (score 21-30) poor (score 0-20)
8 weeks
Primary Nutrition consumption behaviour score To determine changes in nutrition consumption behavior in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Behaviour score(10 questions): good (score>=30 ) moderate (score 21-30) poor (score 0-20).
8 weeks
Primary Nutritional status by body weight To determine changes in BW (body weight in kg) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in BW, the better. 8 weeks
Primary Nutritional status by body mass index To determine changes in BMI (body mass index in kg/m2) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in BMI, the better.
BMI is calculated as weight in kilograms divided by the square of the height in meters (kg/m2) and is categorized into four groups according to the cutoff points: underweight (<18.5 kg/m2), normal weight (18.5-22.9 kg/m2), overweight (23-24.9 kg/m2), obese grade 1 (=25-29 kg/m2) and obese grade 2 (>29 kg/m2)
8 weeks
Primary Nutritional status by haemoglobin To determine changes in Hb (haemoglobin in mg/dL) level in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in haemoglobin level, the better. 8 weeks
Primary Nutritional status by albumin To determine changes in Albumin level (g/dL) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in albumin level, the better 8 weeks
Secondary Calorie intake Changes in calorie intake between ONS group vs control group after an 8-week intervention. Assessment of calorie intake using NutriSurvey 2007, Food Recall 2x24h & Food Record 3x24h. The higher subject's calorie (kcal) intake ,the better. 8 weeks
Secondary Protein intake Changes in protein intake between ONS group vs control group after an 8-week intervention. Assessment of protein intake using NutriSurvey 2007, Food Recall 2x24h & Food Record 3x24h. The higher subject's protein (gram) intake ,the better 8 weeks
Secondary Quality of life with QLC-30 score The change in quality of life between ONS group vs control group; assessed by QLC-C30 (Quality of Life Questionnaire Core-30) score after 8 weeks of intervention. QLC-C30 is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients.
Interpretation of QLC-C30 score: a.Good =1000 b.Moderate = 500-1000 c.Poor =500
8 weeks
Secondary Inflammatory status by CRP The change in inflammatory status between ONS group vs control group assessed by CRP(C-reactive protein in mg/L) level (using CRP Latex Kit) after the 8-week intervention. The lower the value of CRP, the better. 8 weeks
Secondary Inflammatory status by IL-1 The change in inflammatory status between ONS group vs control group assessed by IL-1 (interleukin-1 in pg/ml) level (using IL-1 ELISA kit) after the 8-week intervention The lower the value of IL-1, the better. 8 weeks
Secondary Inflammatory status by IL-6 The change in inflammatory status between ONS group vs control group assessed by IL-6 (interleukin-6 in pg/ml) level (using IL-6 ELISA kit) after the 8-week intervention. The lower the value of IL-6, the better. 8 weeks
Secondary Inflammatory status by TNF-a The change in inflammatory status between ONS group vs control group assessed by TNF-a (Tumor necrosis factor alpha in pg/ml) level (using Kit Quantikine ELISA Human TNF- a) after the 8-week intervention. The lower the value of TNF-a, the better. 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06152419 - Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project N/A
Recruiting NCT04105647 - Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study N/A
Completed NCT05732350 - Exploratory Drug Interaction Study Between SMIs and DOACs
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Active, not recruiting NCT04396457 - Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 Phase 2
Recruiting NCT06391749 - Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Completed NCT04788147 - Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X) N/A
Not yet recruiting NCT06035731 - Evaluation of the Medical Service by Socio-aesthetics in Oncology N/A
Recruiting NCT03274349 - Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma N/A
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02991677 - Exercise Effect on Chemotherapy-Induced Neuropathic Pain N/A
Completed NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Recruiting NCT04859400 - Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients N/A
Recruiting NCT05948865 - A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04270890 - Investigation of an Abdominal Compression Device N/A
Not yet recruiting NCT05154474 - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Not yet recruiting NCT05857995 - Precision Lung Cancer Survivorship Care Intervention N/A